Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective.
It is increasingly likely that non-cardiac-related drugs will need to be routinely analyzed for their ability to prolong cardiac repolarization. This leads to potential problems for drug companies in general and statisticians in particular. A number of issues immediately arise in regard to answering the question, "Does drug X prolong cardiac repolarization?" These include identifying what is the desired outcome, what is the dependent variable, and what analysis method should be used. The purpose of this article is bring to to light some of the issues regarding the analysis of QTc data, the advantages and disadvantages of these analysis methods, and some general recommendations.
Bonate
P L
PL
Quintiles, Inc. Clinical Pharmacokinetics, Kansas City, Missouri 64134, USA.
Russell
T
T
D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015195:Drug Design; D004341:Drug Evaluation; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced / Q000503:physiopathology*
D002316:Cardiotonic Agents